PMID- 2718486
OWN - NLM
STAT- MEDLINE
DCOM- 19890616
LR  - 20191029
IS  - 1042-9611 (Print)
IS  - 1042-9611 (Linking)
VI  - 23
IP  - 1
DP  - 1989 Jan
TI  - Home intermittent amrinone infusions in terminal congestive heart failure.
PG  - 59-62
AB  - The prevalence of congestive heart failure (CHF) and its progressive degenerative 
      course continue to generate pressure for alternative, more effective means of 
      treatment. A confluence of factors, including the number of Americans with CHF, 
      the spiraling costs of hospital care, and increasing interest in cost-effective 
      home care, contribute to the current efforts to develop an effective, nontoxic 
      therapy that effectively increases myocardial contractility and output and can be 
      administered within the confines of the home. Given that preliminary clinical 
      trials in the hospital setting with amrinone have produced positive results, the 
      transition of this therapy to the home, when administered intermittently via 
      central venous catheter and infusion pump, was undertaken. In order to prolong 
      and increase quality of life in terminal CHF patients, intermittent amrinone 
      infusions were provided at home to four patients as part of our pilot program. 
      All four patients met the criteria for New York Heart Association (NYHA) 
      functional class IV heart failure, and none had responded to conventional therapy 
      suitable for outpatient maintenance. The patients also shared strong family 
      support and an intense desire to improve the quality of remaining life. All four 
      patients and designated family members were trained in the specifics of aseptic 
      technique, medication dose preparation, central venous catheter care, and 
      operation of an infusion pump. An ambulatory pump was used in three of the four 
      patients. Subsequent to the initiation of intermittent home amrinone infusions, 
      all four patients had greater tolerance to limited exercise and/or ambulation 
      secondary to increased cardiac output and diuresis. Patients survived 8, 10, 47, 
      and 56 weeks.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Baptista, R J
AU  - Baptista RJ
AD  - Deaconess Home Health Care Corporation, Boston, MA 02215.
FAU - Mitrano, F P
AU  - Mitrano FP
FAU - Perri-LaFrancesca, J
AU  - Perri-LaFrancesca J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - DICP
JT  - DICP : the annals of pharmacotherapy
JID - 8904338
RN  - JUT23379TN (Amrinone)
SB  - IM
MH  - Aged
MH  - Amrinone/*administration & dosage
MH  - Drug Administration Schedule
MH  - Heart Failure/*drug therapy
MH  - *Home Nursing/economics
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Quality of Life
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
AID - 10.1177/106002808902300114 [doi]
PST - ppublish
SO  - DICP. 1989 Jan;23(1):59-62. doi: 10.1177/106002808902300114.